Phanuphak N, Gulick RM. HIV treatment and prevention 2019 current standards of care. Curr Opin HIV AIDS. 2020;15:4–12.

Article  PubMed  Google Scholar 

Singh G, Pai RS. Recent advances of resveratrol in nanostructured based delivery systems and in the management of HIV/AIDS. J Control Release. 2014;194:178–88.

Article  CAS  PubMed  Google Scholar 

Nayak D, Boxi A, Ashe S, Thathapudi NC, Nayak B. Stavudine loaded gelatin liposomes for HIV therapy: Preparation, characterization and in vitro cytotoxic evaluation. Mater Sci Eng C. 2017;73:406–16.

Article  CAS  Google Scholar 

UNAIDS, Global HIV. & AIDS statistics — 2022 fact sheet, (2022).

HIV/AIDS. https://www.who.int/news-room/fact-sheets/detail/hiv-aids.(2019),Accessed date: 17 April 2020.

Surve DH, Jindal AB. Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs. J Controlled Release. 2020;324:379–404.

Article  CAS  Google Scholar 

Esparza J. A brief history of the global effort to develop a preventive HIV vaccine. Vaccine. 2013;31:3502–18.

Article  PubMed  Google Scholar 

Sashindran VK, Chauhan R. Antiretroviral therapy: shifting sands. Med J Armed Forces India (2016).

Ananworanich J, Sacdalan CP, Pinyakorn S, Chomont N, de Souza M, Luekasemsuk T, Schuetz A, Krebs SJ, Dewar R, Jagodzinski L. Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. J Virus Erad. 2016;2:43.

Article  PubMed  PubMed Central  Google Scholar 

N.Ford J, Lee I, Andrieux-Meyer A. Calmy. Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. HIV/AIDS (, Auckland. NZ). 3 (2011) 35–44.

Ferretti F, Boffito M. Rilpivirine long-acting for the prevention and treatment of HIV infection. Curr Opin HIV AIDS. 2018;13:300–7.

Article  CAS  PubMed  Google Scholar 

Kovarova M, Council OD, Date AA, Long JM, Nochii T, Belshan M, Shibata A, Vincent H, Baker CE, Thayer WO, Kraus G, Lachaud-Durand S, Williams P, Destache CJ. J. V. Garcia. Nanoformulations of Rilpivirine for Topical Pericoital and systemic Coitus-Independent Administration efficiently prevent HIV Transmission. PLoS Pathog. (2015)1–19.

Baert L, van’t Klooster G, Dries W, Franc¸ois M, Wouters A, Basstanie E, et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (tmc278) for hiv treatment. Eur J Pharm Biopharm. 2009;72:502–8.

Article  CAS  PubMed  Google Scholar 

Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-hiv drugs. AdvDrug Deliv Rev. 2010;62:491–502.

Article  CAS  Google Scholar 

kommavarapu P, Maruthapillai A, Palanisamy K, Sunkara M. Preparation and characterization of rilpivirine solid dispersions with the application of enhanced solubility and dissolution rate. BENI – SUEF Univ J Basic Appl Sci. 2015;4:71–9.

Google Scholar 

Ahad A, Raish M, Ahmad A, Al-Jenoobi FI, Al-Mohizea AM. Eprosartan mesylate loaded bilosomes as potential nano-carriers against diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharm Sci. 2018;111:409–17.

Article  CAS  PubMed  Google Scholar 

Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm. 2011;420:1–10.

Article  CAS  PubMed  Google Scholar 

Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discovery Today. 2007;12:1068–75.

Article  CAS  PubMed  Google Scholar 

Zhang X, Zhang T, Lan Y, Wu B, Shi Z. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin inclusion complexes for oral bioavailability enhancement via Improved Dissolution and Permeability. AAPS PharmSciTech. 2016;17:400–8.

Article  PubMed  Google Scholar 

Nayak D, Ashe S, Rauta PR, Nayak B. Biosynthesis, characterisation and antimicrobial activity of silver nanoparticles using Hibiscus rosa-sinensis petals extracts. Nanobiotechnol IET. 2015;9:288–93.

Article  Google Scholar 

Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, Kingsley J, Gorantla S, Poluektova L, Nelson JA, Chaubal M. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood. 2006;108:2827–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

das Neves J, Nunes R, Rodrigues F, Sarmento B. Nanomedicine in the development of anti-HIV microbicides. Adv Drug Deliv Rev. 2016;103:57–75.

Article  CAS  PubMed  Google Scholar 

Mamo T, Moseman EA, Kolishetti N, Salvador-Morales C, Shi J, Kuritzkes DR, Langer R, von Andrian U. Farokhzad. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine. 2010;5:269–85.

Article  CAS  PubMed  Google Scholar 

das Neves J, Amiji MM, Bahia MF, Sarmento B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv Drug Deliv Rev. 2010;62:458–77.

Article  CAS  PubMed  Google Scholar 

Baert L, van ’t Klooster G, Dries W, et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm. 2009;72:502–8.

Article  CAS  PubMed  Google Scholar 

Mukadam IZ, Machhi J, Herskovitz J, Hasan M, Oleynikov MD, Blomberg WR, Svechkarev D, Mohs AM, Zhoud Y, Dash P, McMillan J, Gorantla S, Garrison J, Gendelman HE. Kevadiya. Rilpivirine-associated aggregation-induced emission enables cell-based nanoparticle tracking. Biomaterials. 2020;231:1–34.

Article  Google Scholar 

Kevadiya BD, Otteman B, Mukadam IZ, Castellanos L, Sikora K, Hilaire JR, Machhi J, Herskovitz J, Soni D, Hasan M, Zhang W, Anandakumar S, Garrison J, McMillan J, Edagwa B, Mosley RL, Vachet RW, Gendelman HE. Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues. Theranostics. 2020;10:630–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev. 2001;47:55–64.

Article  CAS  PubMed  Google Scholar 

Roger E, Lagarce F, Garcion E, et al. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomed (Lond). 2010;5:287–306.

Article  CAS  Google Scholar 

Arzani G, Haeri A, Daeihamed M, et al. Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge. Int J Nanomed. 2015;10:4797–813.

CAS  Google Scholar 

Stojancevic M, Pavlovic N, Golocorbin-Kon S, Mikov M. Application of bile acids in drug formulation and delivery. Front Life Sci. 2014;7:112–22.

Article  Google Scholar 

He H, Lu Y, Qi J, Zhu Q, Chen Z. Wu. Adapting liposomes for oral drug delivery. Acta Pharm Sinica B. 2019;9:36–48.

Article  Google Scholar 

Waglewska E, Pucek-Kaczmarek A. Bazylińska. Novel surface-modified bilosomes as Functional and Biocompatible nanocarriers of Hybrid compounds. Nanomaterials (Basel). 2020;10:2472.

Article  CAS  PubMed  Google Scholar 

Zang H, Fofana J, Xu F, Nodder SB, Gummuluru S. Reinhard. Characterizing lipid-coated mesoporous silica nanoparticles as CD169-Binding delivery system for Rilpivirine and Cabotegravir. Adv Nanobiomed Res. 2022;2:1–24.

Article  Google Scholar 

Eshaghi B, Fofana J, Nodder SB, Gummuluru S, Reinhard BM. Virus-mimicking polymer nanoparticles targeting CD169 + macrophages as Long-Acting Nanocarriers for Combination antiretrovirals. ACS Appl Mater Interface. 2022;14:2488–500.

Article  CAS  Google Scholar 

Waglewska E, Pucek-Kaczmarek A, Bazylinska U. Self-assembled bilosomes with stimuli-responsive properties as bioinspired dual-tunable nanoplatform for pH/ temperature-triggered release of hybrid cargo. Colloids Surf B Biointerfaces. 2022;215:112524.

Article  CAS  PubMed  Google Scholar 

Elkomy MH, Alruwaili NK, Elmowafy M, Shalaby K, Zafar A, Ahmad N et al. 2022. Surface-modified bilosomes nanogel bearing a natural plant alkaloid for safe management of rheumatoid arthritis inflammation. Pharmaceutics 14 (2022).

Venkatesan S, Kannappan N. Simultaneous Spectrophotometric Method for Determination of Emtricitabine and Tenofovir Disoproxil Fumarate in three-component tablet Formulation Containing Rilpivirine Hydrochloride. Int Sch Res Notices (2014) 1–8.

Vijaya Sri K, Jain GV, Madhuri M. UV-Visible Spectrophotometric Method for the estimation of Rilpivirine Hydrochloride in Pharmaceutical Dosage Form by using multivariate technique. Chem Sci Trans. 2015;4:799–805.

Google Scholar 

Liu K, H